Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189174 · ClinicalTrials.gov registry record · Phase 1
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02189174 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT02189174, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
Interventions
- DRUG CLR457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-08-07 |
| Est. Completion | 2015-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189174
The ClinicalTrials.gov registry entry for NCT02189174 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CLR457 is the first listed.
NCT02189174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189174 about?
NCT02189174 is a clinical study titled "Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies". To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
What is the current status of trial NCT02189174?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-08-07. Estimated completion is 2015-11-12.
What interventions are being tested in trial NCT02189174?
The interventions under investigation include: CLR457 (DRUG).
Who is sponsoring clinical trial NCT02189174?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.